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Background: Publicly funded trials regularly fail to recruit their target sample size or find a significant positive
result. Adaptive clinical trials which may partly mediate against the problems are not often applied. In this paper
we investigate the potential of a form of adaption in a clinical trial - a futility analysis - to see if it has potential to
improve publicly funded trials.
Methods: Outcome data from trials funded by two UK bodies, the Health Technology Assessment (HTA)
programme and the UK Medical Research Council (MRC), were collected. These data were then used to simulate
each trial with a single futility analysis using conditional power, undertaken after 50% to 90% of the patients had
been recruited. Thirty-three trials recruiting between 2002 and 2008 met the inclusion criteria. Stopping boundaries
of conditional powers of 20%, 30% and 40% were considered and outcomes included the number of trials
successfully stopped and number of patients saved.
Results: Inclusion of a futility analysis after 75% of the patients had been recruited would have potentially resulted
in 10 trials, which went on to have negative results, correctly stopping for futility using a stopping boundary of
30%. A total of 807 patients across all the trials would potentially have been saved using these futility parameters.
The proportion of studies successfully recruiting would also have increased from 45% to 64%.
Conclusions: A futility assessment has the potential to increase efficiency, save patients and decrease costs in
publicly funded trials. While there are logistical issues in undertaking futility assessments we recommend that
investigators should aim to include a futility analysis in their trial design wherever possible.
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Publicly funded trials in the United Kingdom (UK) have
poor rates of recruitment [1,2], with only just over half
successfully recruiting to their initial target sample size.
A consequence of poor recruitment is that a trial can
have reduced power. An underpowered trial may in turn
be considered to be unethical, as the probability of find-
ing a specified effect size in the trial would be so low
that patients would enter into a trial which has little
chance of achieving its objectives.
Trials with poor recruitment may also be more likely
to request an extension to attempt to reach their target
sample size. Between 2002 and 2008 nearly half of all
publicly funded trials received an extension of some kind* Correspondence: s.a.julious@sheffield.ac.uk
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unless otherwise stated.[1], with similar results found between 1994 and 2002
[2]. The extension may be either time-based, cost-based
or both.
Innovative trial designs have been applied to avoid this
problem in the pharmaceutical industry [3], where the
main concerns include regulatory requirements, the need
to get to market quickly and the necessity to develop only
the most promising interventions [4]. Usually a pharma-
ceutical company would be undertaking trials to obtain
sufficient evidence to get a license for a new treatment. As
such, trials with negative results could mean a treatment
does not get a license.
Publicly funded trials, such as those funded by the UK
Medical Research Council (MRC) or National Institute for
Health Research (NIHR) Health Technology Assessment
programme (HTA), have different practical issues. For
example, the trials may be assessing treatments whichd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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required to get them used in practice. Valuable infor-
mation is still obtained regardless of the final result [5].
Indeed, between 1993 and 2008 only 19% of superior-
ity trials funded by the HTA programme had a statisti-
cally significant and clinically important result [6], with
76% of trials having results that were not statistically
significant.
Interventions are often complex [6] in publicly funded
trials. The outcomes are multi-faceted, often incorporating
efficacy, quality of life and health economics, evaluating
not just whether an intervention works but also if it
offers value for money [5]. This increases the complex-
ity of the whole trial. These practicalities, along with
slow recruitment, can have a negative impact on trial
duration [7-9].
Methods to improve the overall efficiency of clinical
trials must account for the practical difficulties in
undertaking the studies; it is the logistics and not the
statistics which most impact a trial design [10]. Methods
that are regularly applied in pharmaceutical trials may
not be appropriate for publicly funded trials. Adaptive
designs are one of the methods that are regularly ap-
plied in industry but have for the most part not been
used in the public sector [11]. Principles such as sam-
ple size re-estimation, futility analysis and group se-
quential designs all have the potential to maximise
efficiency and minimise costs in clinical trials. These
methods have been shown to be statistically valid; it is
often practical and expertise issues which prevent their
use [11].
This paper will focus on futility assessment during a trial
as a method for stopping trials which have low chances of
finding a statistically significant result. We have applied
existing conditional power methods for futility analysis
retrospectively to the database of trials used by Sully et al.
[1]. The results have been used to give an indication of the
potential savings in patients, time and, by extension, costs
that could be brought about by including futility analyses
in publicly funded trials.
Methods
Data collection
Analysis was undertaken using the trial database created
by Sully et al. [1] with some added restrictions to sim-
plify interpretation. Trials were eligible if they met the
following inclusion and exclusion criteria taken from
Sully et al.:
1. They were multicentre.
2. Recruitment started on or after 1 January 2002.
3. Recruitment was originally planned to close on or
before 31 December 2008.
4. They were not a cluster randomised trial.Additional inclusion and exclusion criteria added were
as follows:
1. They were a two-armed, parallel group superiority
study.
2. The primary endpoint was binary or continuous.
3. They had evidence of a sample size calculation.
4. Data relating to the endpoint used in the sample
size calculation were available at follow-up.
We restricted the studies to binary and continuous
outcomes as in these cases it was always possible to de-
termine the treatment effects in the trials and undertake
calculations using summary data.
The existing database was sufficient for identifying
most trials and further data extraction was undertaken
to obtain the planned and observed effect sizes and type
of endpoint for each trial. While utmost care went into
ensuring that extracted data were correct there were oc-
casional ambiguities in reporting; in these cases trial
managers were contacted for clarification. In the event
that no response was received, the trial was excluded
from the study.
The types of data collected, split by endpoint (binary
or continuous), are shown in Table 1. The aim was to
collect the data to best allow for calculation of estimates
of the conditional power and to inform the simulations:
number of successes/failures in each group for binary
outcomes and mean/standard deviation/sample size in
each group for continuous outcomes. Unadjusted values
were used for continuous outcomes.
Trials were also broken down into those which were
‘successful’ and those that were not. For this paper a
successful trial is primarily defined as a trial finding a
treatment effect greater than or equal to that specified
in the sample size calculation; it was not necessary for
this effect to be statistically significant. This is because
in publicly funded trials it is not just important to see a
statistically significant effect, but to see a worthwhile
effect size; there are often many secondary endpoints, so
the primary endpoint being non-significant does not
mean the trial has failed to be worthwhile [5]. The final
column of Table 1 gives the number of studies that were
‘successful’. The row for gastroenterology was included des-
pite having zero numbers for consistency with the original
paper where there were studies [11]. With respect to clin-
ical area our data are too sparse to draw any conclusions.
As a secondary analysis the data were re-investigated with
the requirement that the primary outcome must be statisti-
cally significant for a trial to be considered successful.
Statistical methods
For each trial, a simulation was run using the planned
sample size of the trial and observed number of successes
Table 1 Characteristics of trials
Trial characteristics Number (%) Mean (SD) Minimum - maximum Successful (%)
Funding body HTA 15 (45.4) 4 (26.7)
MRC 18 (54.5) 4 (22.2)
Endpoint Binary 20 (60.6) 4 (20.0)
Continuous 13 (39.4) 4 (30.8)
Disease Cancer 2 (6.1) 0 (0.0)
Area Mental health (including neurosciences/
psychiatry/psychology)
5 (15.2) 3 (60.0)
Orthopaedics/rheumatology (including back pain) 1 (3.1) 0 (0.0)
Obstetrics & gynaecology 2 (6.1) 1 (50.0)
Primary care 7 (21.2) 2 (28.6)
Cardiology 3 (9.1) 0 (0.0)
Gastroenterology 0 (0.0) 0 (0.0)
Incontinence/urology 2 (6.1) 0 (0.0)
HIV/AIDS 1 (3.0) 0 (0.0)
Other 10 (30.3) 2 (20.0)
Planned sample size 751.4 (1426.9) 80 to 8,000
Final sample size 615.2 (1452.1) 44 to 8,164
Power 84.2 (5.2) 80 to 95
HTA, Health Technology Assessment; MRC, Medical Research Council; SD, standard deviation.
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continuous trials). Trials were simulated using a binomial
distribution or Normal distribution, as appropriate. The
conditional power of the trial was then calculated at every
10% of the planned sample size (up to the final sample
size, if final recruitment was below that planned), as well
as after 75%, using the methods shown below. Each simu-
lation was repeated 50,000 times. The mean conditional
power was calculated at each proportion of the sample
size for each trial and used to judge whether a trial should
be stopped for futility using a boundary, γ, of either γ = 0.2,
γ = 0.6 or γ = 0.4. Thus, for the first boundary value, if the
conditional power is less than 0.2, for instance, then the
study will stop early for futility.
When calculating the conditional power of a trial an
assumption must be made about the distribution of the
remainder of the trial data. Three common choices are
that it will follow the null hypothesis, the alternative hy-
pothesis or the observed trend so far [12]. In this paper,
we assume the data will follow the alternative hypoth-
esis. This gives trials the least chance of stopping early,
and so maximises information. The conditional power















;where Φ is the cumulative density function of the stand-
ard Normal distribution, Ζ is the standard Normal
random variable, Ζt is the Ζ-score at interim, τ is the
proportion of patients recruited, and α and 1-β are the
planned type I and II errors, respectively. Conditional
power was calculated on a two-sided basis, so the con-
ditional power was the probability of finding either a
significant positive or negative result.
In our analysis the assumption is that only one assess-
ment of futility is planned in the study.
We also make the additional assumption that we have
all patients recruited available who have been recruited
for the futility assessment. The implications of this
assumption will be discussed later.
As highlighted, one of the assumptions is that the
remainder of the trial will follow the alternative hypothesis.
Thus, the estimate of effect will be taken from that used in
the sample size calculation. If the effect in this original
calculation was overstated then the conditional power will
be low and a trial will stop for futility even when a possibly
clinically meaningful difference has been observed [13].
The results in this paper are particularly sensitive to
this assumption as we define ‘success’ as observing the
pre-specified estimate of effect.
Results
The seventy-three trials from the previous database [1]
were assessed for eligibility; Figure 1 shows the flow of
Figure 1 Flow of trials through the study.
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trials were eligible; the main reasons for ineligibility were
a trial having more than two arms (12; 16%), the main
trial objective being non-inferiority or equivalence (7; 10%),
the trial not having appropriate data available (7; 10%)
or not having a power calculation (6; 8%). Characteris-
tics of eligible trials are shown in Table 1. Eight of the tri-
als were successful (24%). This result is consistent with
Dent and Raftery [6] who used a definition of statistically
significant (and observed 26% of trials) and statistically
significant with clinically meaningful effects (and observed
19% of trials).
Figure 2 shows the average conditional power of each
trial from the simulations. Trials are broken down into
those that were successful and those that were not using
our primary definition of successful. One trial had low
conditional power towards the end of recruitment des-
pite finding an effect larger than planned (relatively): this
is due to the lack of statistical significance found by the
trial, that is P-values of P = 0.050 [7]. This was due to the
observed response rates being different than assumed.
Conversely, one trial had very high average conditional
power despite finding an effect much smaller than origin-
ally planned; this is because the trial undertook a sample
size re-estimation and went on to recruit far more than its
original planned sample size – based on a new effect size -
eventually finding statistically significant evidence but one
that was smaller than used in the original sample size
calculation [14].
The majority of trials which eventually ‘fail’ appear to
have conditional power below 40% by the time 70% of
patients have been recruited, and below 30% by the time80% of patients have been recruited. This is summarised
in Table 2, where results for ‘true success’ versus ‘stop
due to conditional power’ are given for every 10% of
patients after 50% (and at 75% of target recruitment),
and for both 30% and 40% conditional power boundar-
ies. In each of these tables higher numbers in the off-
diagonals are desirable, as this indicates that either: 1)
trials have found a successful result and would not have
been stopped due to futility, had an analysis been done;
or 2) trials have not found a successful result and would
have been stopped due to futility.
It is important to avoid false negatives – in this case,
higher numbers in the top-left cell of the tables – as this
indicates a trial has been stopped due to futility, when it
would have been successful had it continued. One trial
could be considered to have incorrectly stopped for futility
in our analysis (Table 2). This study found a statistically
significant result but a very small effect size, so it is
classified as unsuccessful by our definitions. This trial
would have been stopped for futility after 80% or more
of patients had been recruited using a 40% stopping
boundary.
The analysis was repeated using our secondary defin-
ition of a successful trial – that the trial has a ‘statisti-
cally significant’ outcome. Ten (30%) of the trials were
considered successful using this classification compared to
eight (24%) using the previous definition; this is higher
because of statistically significant results for effects smaller
than planned on the sample size. Table 3 shows the same
summary as Table 2 using this alternative classification.
It is worth noting that for both Table 2 and Table 3
there are a different number of studies which recruit
Figure 2 Conditional power of each trial as simulated patients are recruited. Black lines indicate 30% and 40% conditional power boundaries.
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ple size [1], falling from 29 studies that achieved 50% of
their target sample size to 20 that reached 90%.
For our analysis we are concerned with the overall
proportion of trials, particularly how a futility assessment
will impact on the proportion of trials that successfully
recruit to their target sample size. It is worth highlighting,
however, that trials that continue after a futility assess-
ment will not necessarily go on to be successful. With a
futility assessment after 70%, 80% and 90% of patients,Table 2 Number and percentage of trials stopping for futility af
based on stopping boundaries of 20%, 30% or 40%
Number (percentage) of trials
Stop if futility analysis done 50% of patients Stopped early Yes
No
60% of patients Stopped early Yes
No
70% of patients Stopped early Yes
No
75% of patients Stopped early Yes
No
80% of patients Stopped early Yes
No
90% of patients Stopped early Yes
No
CP, conditional power.62% (8 of 13), 64% (7 of 11) and 50% (4 of 8), respectively,
would still go on to be unsuccessful according to Table 3
with a 30% conditional power boundary (it should be
noted that these numbers are based on a small number of
trials). We did not consider minimising the proportion of
trials which go on to be unsuccessful which would be the
case with higher conditional power at a futility assessment.
Table 4 shows the potential saving in patients across all
33 trials had a futility analysis been undertaken. Maximum








Successful trial Successful trial Successful trial
Yes No Yes No Yes No
0 0 0 0 0 0
8 (28%) 21 (72%) 8 (28%) 21 (72%) 8 (28%) 21 (72%)
0 0 0 3 (12%) 0 8 (32%)
5 (20%) 20 (80%) 5 (20%) 17 (68%) 5 (20%) 12 (48%)
0 5 (21%) 0 11 (46%) 0 12 (50%)
5 (21%) 14 (58%) 5 (21%) 8 (33%) 5 (21%) 7 (29%)
0 7 (30%) 0 10 (43%) 0 14 (61%)
4 (17%) 12 (52%) 4 (17%) 9 (39%) 4 (17%) 5 (22%)
0 9 (41%) 0 11 (50%) 1 (5%) 14 (64%)
4 (18%) 9 (41%) 4 (18%) 7 (32%) 3 (14%) 4 (18%)
0 11 (55%) 0 12 (60%) 1 (5%) 15 (75%)
4 (20%) 5 (25%) 4 (20%) 4 (20%) 3 (15%) 1 (5%)
Table 3 Number and percentage of trials stopping for futility when requiring a statistically significant result to
consider a trial ‘successful’







Successful trial Successful trial Successful trial
Yes No Yes No Yes No
Stop if futility analysis done 50% of patients Stopped early Yes 0 0 0 0 0 0
No 9 (31%) 20 (69%) 9 (31%) 20 (69%) 9 (31%) 20 (69%)
60% of patients Stopped early Yes 0 0 0 3 (12%) 1 (4%) 7 (28%)
No 6 (24%) 19 (76%) 6 (24%) 16 (64%) 5 (20%) 12 (48%)
70% of patients Stopped early Yes 0 5 (21%) 0 11 (46%) 0 12 (50%)
No 5 (21%) 14 (58%) 5 (21%) 8 (33%) 5 (21%) 7 (29%)
75% of patients Stopped early Yes 0 7 (30%) 0 10 (43%) 0 14 (61%)
No 4 (17%) 12 (52%) 4 (17%) 9 (39%) 4 (17%) 5 (22%)
80% of patients Stopped early Yes 0 9 (41%) 0 11 (50%) 0 15 (68%)
No 4 (18%) 9 (41%) 4 (18%) 7 (32%) 4 (18%) 3 (14%)
90% of patients Stopped early Yes 0 11 (55%) 0 12 (60%) 0 16 (80%)
No 4 (20%) 5 (25%) 4 (20%) 4 (20%) 4 (20%) 0
CP, conditional power.
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tients) and a γ = 0.40 boundary (1,390 patients).
Numbers and percentages of trials considered to have
‘successfully recruited’ after undertaking a futility analysis
are given in Table 5. For this table we have coded a trial as
successfully recruited to target if it stops for futility, re-
gardless of whether the trial then went on to meet its ori-
ginal target sample size.
Undertaking a futility analysis after 50% of patients have
been recruited leaves the proportions unchanged: 15
(45%) of the trials are classed as successfully recruiting.
This proportion is highest (21 trials; 64%) when the futility
analysis is undertaken after 70% or 75% of patients are
recruited. It should be noted that because some of the
trials failed to ever reach higher proportions of their target
sample size (80% or 90%) they would not have had chance
to undertake a futility assessment.Table 4 Number of patients potentially saved
Number of patients saved
(after inflation in sample size)
Stopping boundary
20% 30% 40%
Proportion of patients recruited 50% 0 0 0
60% 0 325 751
70% 342 686 1,027
75% 634 807 1,390
80% 512 667 1,145
90% 467 570 711Discussion
We recommend that a futility assessment be considered
for all trials and in particular for publicly funded trials.
With a futility assessment there is the potential to con-
siderably increase the proportion of trials that success-
fully recruit to the target sample size. There would need
to be a small inflation in the target sample size but this
would be offset by the savings made from the trials stop-
ping early.
Including a futility assessment can increase the chances
of a study successfully recruiting. In our analysis, with a
futility assessment after 75% of the target sample size hasbeen recruited, the proportion of studies successfully
recruiting can be increased from 45% to 64%.
It should be noted, however, that a futility assessment
will not ensure the trial goes on to be successful. In our
analysis with a futility assessment after 75% of patients
with conditional power of 30% the majority of trials - 69%
(9 of 13) - would still go on to be unsuccessful. Altering
the conditional power at the futility assessment will have
an impact on the proportion of trials that go on to be
successful.
In our study, only 24% of trials were successful by our
definition which was consistent with the work of Dent
and Raftery using slightly different definitions [6]. If the
prevalence of successful trials is different, then the po-
tential savings in terms of sample sizes will vary. It is
likely that the chance of a successful trial will vary by
disease area. However, in our study the data are too
sparse to draw any firm conclusions.




CP stopping boundary 20% CP stopping boundary 30% CP stopping boundary 40%
Yes No Yes No Yes No
50% of patients 15 (45%) 18 (55%) 15 (45%) 18 (55%) 15 (45%) 18 (55%)
60% of patients 15 (45%) 18 (55%) 17 (52%) 16 (48%) 21 (64%) 12 (36%)
70% of patients 19 (58%) 14 (42%) 20 (61%) 13 (39%) 21 (64%) 12 (36%)
75% of patients 19 (58%) 14 (42%) 21 (64%) 12 (36%) 21 (64%) 12 (36%)
80% of patients 19 (58%) 14 (42%) 20 (61%) 13 (39%) 20 (61%) 13 (39%)
90% of patients 19 (58%) 14 (42%) 19 (58%) 14 (42%) 19 (58%) 14 (42%)
CP, conditional power.
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analysis earlier in a trial, which allows for greater oppor-
tunity for savings in the sample size compared to under-
taking a futility assessment later when a trial is more
likely to be correctly designated as futile. In our analysis,
we found that a futility assessment after at least 70% of
the target sample size has been recruited maximised the
chances of stopping for futility with little chance of
stopping after 50% of the target sample size. Our results
are consistent with those of Lachin [15]. Assuming the
remainder of the trials followed the alternative hypothesis,
thus author's study found that if there was no difference
observed in the trial the conditional power would still be
above 25% after 50% of patients (and a little short of 30%).
The issue of early futility assessment can be illustrated
with simple calculations. Imagine a conventional sample
size calculation where the sample size, n, is estimated
for a clinically significant difference, d, for 90% power
and a two-sided significance level, 5% [16]. Suppose half
way through a naïve power calculation was done taking
the simple mean of the observed effect for the first 50%
of patients and the anticipated effect for the remainder
of the trial, d (and standard deviation, σ). If the observed
effect was zero (with the standard deviation observed, s,
the same as σ) then the simple average would be d/2 and
the naïve power calculation would be 37%. Thus, half
way through the trial, the effect size (assuming other
assumptions used in the sample size are consistent, such
as the estimate of the population standard deviation) can
be small and the study may still not stop for futility.
Futility assessments are not without their downsides.
Introducing an extra chance to stop the trial due to lack
of a positive result will increase the Type II error β up to





(equivalent to a decrease in power from 90% to 85.7%
for γ = 0.30); however, this maximum is only reached if
the trial is continuously monitored for futility [12]. Changand Stein [17], highlight, though, that with a futility as-
sessment the Type I error also is reduced which,when
accounted for, offsets the need to inflate sample size due
to a loss of power.
Conservatively, we can ignore the effect on the Type I
error and adjust the sample size to account for the
impact on the power. It has been suggested that for one
futility analysis the associated decrease in power is rela-
tively small provided the boundary γ is less than or equal
to 40% [17]. Using a boundary of this size, power is
decreased to a minimum of 97% of the previous value,
so the sample size of a 90% powered study should be
inflated by a maximum of 10% to account for this loss in
power.
It should be noted, however, that the reduction in
power will depend both on the timing of the futility
assessment and the conditional power boundary used,
and will usually be much lower than this. For example,
assessing futility after 75% of patients are recruited using
a 30% boundary will only inflate the sample size of a
90% powered study by approximately 6%, and this would
be less if the futility assessment is earlier. Investigators
can determine this inflation themselves using avail-
able statistical software [18] with appropriate stopping
boundaries [19].
Although there needs to be an adjustment in the max-
imum planned sample size when designing the study,
the number of patients who are recruited into the study
may well be considerably less than this maximum. This
is because, as we have observed in this paper, if the null
hypothesis is true the actual sample size would be con-
siderably smaller as the study would stop for futility.
It should be noted that the methods applied and
results obtained in this paper assume that the time be-
tween recruitment and primary outcome measurement
(t) is very small relative to the total time spent recruiting
(T), that is, t/T is small. This assumption means that
when assessing futility after n0 evaluable patients have
been recruited, outcome data will be available on all of
them. However, if this assumption does not hold and t/T
is not small there will be those who have been recruited
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futility assessment. These patients are known as pipeline
patients [20].
We observed that the optimum time to undertake a
futility analysis is after 75% of patients of the target
sample size have been recruited. In actuality, this is 75%
of patients for whom we have an assessment at the rele-
vant endpoint. Hence, a futility assessment requiring 75%
of evaluable patients may now encounter the problem of
having fully recruited at the time of the assessment. De-
noting the number of patients recruited (evaluable or not)
by nr and the planned sample size by N, in this case we
find that
nr ¼ 0:75þ tT
 
N





patients. Clearly if t/T ≥0.25 then there is little benefit
to be gained from a futility assessment as the trial will
have fully recruited. The results found in this paper are,
therefore, indicative of the maximum savings attained if
the time between recruitment and outcome is very short
relative to the total recruitment time of the trial, such
as, for example, trials in emergency medicine [21].
In cases where the follow-up time for the primary out-
come is relatively long, alternative methods must be
considered. Hampson and Jennison discuss this situation
in detail, proposing methods for delayed responses
which include analysis of pipeline data [20].
The implication of what we have highlighted is that
the potential reductions in the sample size highlighted in
Table 4 are maximum potential sample size reductions,
achievable in some areas where the primary outcome is
at an early time point but less so in other areas. A
further issue is that the impact of futility depends on the
proportion of trials where the null hypothesis is true.
This is unknown and will vary from trial to trial.
There are many benefits to including a futility analysis
in a trial. Stopping a futile trial early allows patients who
would otherwise have been assigned to an inferior treat-
ment to instead receive the best possible care. Addition-
ally, with only a finite capacity for research the patients,
no longer being recruited into a stopped trial, could go on
to take part in other, more promising studies. Additionally,
investigators can focus the time saved on further research
rather than completing a negative trial.
Conclusions
A futility assessment in a clinical trial has the potential
to increase efficiency, save patients, and decrease the
costs of publicly funded trials. While there are logisticalissues in undertaking a futility assessment, whenever
possible investigators should aim to include a futility
analysis in their trial design, with the results from the 33
trials in the paper suggesting maximum savings found
by doing so when 75% of the target sample has been
recruited, using a boundary of γ = 0.3.
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